Supernus Pharmaceuticals, Inc. (SUPN) Investor Outlook: A 31% Upside Potential Amid Strong Revenue Growth
Supernus Pharmaceuticals, Inc. (SUPN) is highlighted as a prominent player in CNS therapies with a 31.19% projected upside based on analyst targets, despite recent challenges in profitability. The company boasts strong revenue growth of 32.40% and a healthy free cash flow, indicating potential for …